加拿大卡尔加里大学Derek V. Exner联合阿尔伯塔大学Brian H. Buck团队比较了植入式与长期外部心电图监测对缺血性脑卒中患者房颤检出的影响。2021年6月1日,该成果发表在《美国医学会杂志》上。
缺血性中风后使用外循环记录器或植入式循环记录器对患者进行长期心电图监测,其心房颤动(AF)或心房扑动的相对检出率尚不清楚。
为了确定在近期缺血性中风的患者中,与常规外循环记录器监测30天相比,12个月植入式循环记录器监测是否检测到更多的房颤发生,2015年5月到2017年11月,研究组在加拿大阿尔伯塔省的2所大学医院和1所社区医院进行了一项研究者发起、开放标签、随机临床试验,招募了300名6个月内缺血性中风且无已知房颤的患者;最终随访时间为2018年12月。
将患者按1:1的比例随机分为两组,其中150例使用植入式循环记录仪,150例使用外部回路记录器,随访时间分别为30天、6个月和12个月。主要结局是发生明确的房颤或极有可能的房颤(判定为新房颤,即12个月内随机发作≥2分钟)。共有8个预先指定的次要结局,包括12个月内新发房颤、复发性缺血性中风、脑出血、死亡和设备相关严重不良事件。
300名患者的平均年龄为64.1岁,女性占40.3%,66.3%的患者病因不明,中位CHA2DS2 VASc(充血性心力衰竭、高血压、年龄≥75岁、糖尿病、中风或短暂性脑缺血发作、血管疾病、年龄65-74岁、性别分类)得分为4分。273例患者(91.0%)完成24小时及以上的心脏监护,259例(86.3%)完成指定监护和12个月随访。
植入式线圈记录器组的主要结局发生率为15.3%(23/150),显著高于外部线圈记录器组的4.7%(7/150)。在8个指定的次要结局中,6个没有显著差异。植入式线圈记录器组有5例(3.3%)患者发生复发性缺血性中风,而外部线圈记录器组有8例(5.3%);两组各有1例(0.7%)患者发生脑出血;两组各有3例患者(2.0%)死亡;两组分别有1例(0.7%)与0例(0%)患者发生设备相关的严重不良事件。
研究结果表明,对于缺血性中风且既往无房颤证据的患者,植入式心电图监测12个月,与延长外部监测30天相比,12个月以上检出房颤的患者比例显著增加。
附:英文原文
Title: Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial
Author: Brian H. Buck, Michael D. Hill, F. Russell Quinn, Ken S. Butcher, Bijoy K. Menon, Sajad Gulamhusein, Muzaffar Siddiqui, Shelagh B. Coutts, Thomas Jeerakathil, Eric E. Smith, Khurshid Khan, Phillip A. Barber, Glen Jickling, Lucy Reyes, Supriya Save, Paige Fairall, Lori Piquette, Noreen Kamal, Derek S. Chew, Andrew M. Demchuk, Ashfaq Shuaib, Derek V. Exner
Issue&Volume: 2021/06/01
Abstract:
Importance The relative rates of detection of atrial fibrillation (AF) or atrial flutter from evaluating patients with prolonged electrocardiographic monitoring with an external loop recorder or implantable loop recorder after an ischemic stroke are unknown.
Objective To determine, in patients with a recent ischemic stroke, whether 12 months of implantable loop recorder monitoring detects more occurrences of AF compared with conventional external loop recorder monitoring for 30 days.
Design, Setting, and Participants Investigator-initiated, open-label, randomized clinical trial conducted at 2 university hospitals and 1 community hospital in Alberta, Canada, including 300 patients within 6 months of ischemic stroke and without known AF from May 2015 through November 2017; final follow-up was in December 2018.
Interventions Participants were randomly assigned 1:1 to prolonged electrocardiographic monitoring with either an implantable loop recorder (n=150) or an external loop recorder (n=150) with follow-up visits at 30 days, 6 months, and 12 months.
Main Outcomes and Measures The primary outcome was the development of definite AF or highly probable AF (adjudicated new AF lasting ≥2 minutes within 12 months of randomization). There were 8 prespecified secondary outcomes including time to event analysis of new AF, recurrent ischemic stroke, intracerebral hemorrhage, death, and device-related serious adverse events within 12 months.
Results Among the 300 patients who were randomized (median age, 64.1 years [interquartile range, 56.1 to 73.7 years]; 121 were women [40.3%]; and 66.3% had a stroke of undetermined etiology with a median CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years, diabetes, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category] score of 4 [interquartile range, 3 to 5]), 273 (91.0%) completed cardiac monitoring lasting 24 hours or longer and 259 (86.3%) completed both the assigned monitoring and 12-month follow-up visit. The primary outcome was observed in 15.3% (23/150) of patients in the implantable loop recorder group and 4.7% (7/150) of patients in the external loop recorder group (between-group difference, 10.7% [95% CI, 4.0% to 17.3%]; risk ratio, 3.29 [95% CI, 1.45 to 7.42]; P=.003). Of the 8 specified secondary outcomes, 6 were not significantly different. There were 5 patients (3.3%) in the implantable loop recorder group who had recurrent ischemic stroke vs 8 patients (5.3%) in the external loop recorder group (between-group difference, 2.0% [95% CI, 6.6% to 2.6%]), 1 (0.7%) vs 1 (0.7%), respectively, who had intracerebral hemorrhage (between-group difference, 0% [95% CI, 1.8% to 1.8%]), 3 (2.0%) vs 3 (2.0%) who died (between-group difference, 0% [95% CI, 3.2% to 3.2%]), and 1 (0.7%) vs 0 (0%) who had device-related serious adverse events.
Conclusions and Relevance Among patients with ischemic stroke and no prior evidence of AF, implantable electrocardiographic monitoring for 12 months, compared with prolonged external monitoring for 30 days, resulted in a significantly greater proportion of patients with AF detected over 12 months. Further research is needed to compare clinical outcomes associated with these monitoring strategies and relative cost-effectiveness.
DOI: 10.1001/jama.2021.6128
Source: https://jamanetwork.com/journals/jama/article-abstract/2780491
JAMA-Journal of The American Medical Association:《美国医学会杂志》,创刊于1883年。隶属于美国医学协会,最新IF:51.273
官方网址:https://jamanetwork.com/
投稿链接:http://manuscripts.jama.com/cgi-bin/main.plex
